Overview

The goal of this activity is to understand the challenges of individualized management of CKD-related anemia with a focus on strategies for making treatment decisions and patient-centric treatment plans. Unmet needs of treating anemia of CKD will also be discussed. 

Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 7/8/2020, and they are subject to change as new information is published.

Learning Objectives

  • Recognize the challenges of individualized treatment of CKD related anemia.

Faculty

Steven Fishbane, MD,FACP

Chief of Nephrology of Northwell Health and
Professor of Medicine at the Zucker School of Medicine
Great Neck, NY

Jay B. Wish, MD,FACP

Professor of Clinical Medicine
Indiana University School of Medicine
Indianapolis, IN 

Daniel W. Coyne, MD

Medical Director of Chromalloy American Kidney Center and Director of Outpatient Renal Clinics at Washington University School of Medicine in St. Louis
St Louis, MO 

Disclosures

The following relevant financial relationships have been disclosed by faculty.

Steven Fishbane, MD: Consultant for AstraZeneca, Fibrogen and Akebia.

Jay Wish, MD: Advisory Board for AstraZeneca, Akebia, and Vifor. Consultant for Otsuka. Speaker’s Bureau for Keryx and Pfizer.  

Daniel Coyne, MD: Consultant for FMC-RTG, AstraZeneca, Medibeacon, Reata.  

Martin Quan, MD (Planner): No relevant financial relationships disclosed. 

Cynthia Smith, DNP, CNN-NP, FNP-BC, APR (Planner): Speaker’s Bureau and Consultant for Sanofi Genzyme, Speaker’s Bureau for Abbvie and Relypsa, Consultant for Elsevier and Vifor.   

 

All other contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.   


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and National Kidney Foundation. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308. 


Designation Statement

This program has been approved for 0.70 contact hour of continuing education, which includes 0.70 hour of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

Commercial Supporter

AstraZeneca

Education Partner

National Kidney Foundation



Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.